ClinicalTrials.gg
RecruitingNCT07250347Updated Nov 26, 2025

AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT

An observational study in Gastric Cancer Stage and Gastric Cancer Patients Undergoing Gastrectomy, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
8,000
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University — 21 open to participants now, 24 under way, 2 of them phase 3. Stomach Neoplasms · The First Affiliated Hospital with Nanjing Medical University.

Started
2025
with 3 others
Observational
5 of 28
3 open now
Primary completion
2028-12
later than 20 of 23 live
Registered
22nd of 28
by date

Among the 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University, this one is one of 4 that started in 2025, is one of 5 observational ones, reaches primary completion later than 20 of the 23 other live ones, and was the 22nd registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

21 of the 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University are open now, in 1 country. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 21 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Stomach Neoplasms by The First Affiliated Hospital with Nanjing Medical University, or all of them as a file.
02

Study summary

Accurate preoperative assessment of gastric cancer stage guides eligibility for endoscopic resection, extent of gastrectomy and lymphadenectomy, selection for neoadjuvant therapy, and use of staging laparoscopy. Contrast-enhanced CT (CECT) is guideline-endorsed for initial staging, yet performance varies across institutions and readers. This study will evaluate an artificial-intelligence (AI) system that analyzes routine CECT to detect gastric cancer and assign four-class T stage (T1-T4) and N stage (N0-N3) .

Read the detailed description

Adults with confirmed gastric cancer undergoing pre-treatment CECT will be enrolled. The AI analysis will be applied to clinically acquired images. Radiologist interpretations with and without AI support will be collected in a prespecified reader study. The reference standard will include surgical pathology, supplemented by clinical follow-up when applicable. The primary outcome is detection performance, diagnostic performance of the AI for four-class staging (e.g., accuracy and area under the receiver operating characteristic curve). Secondary outcomes include the effect of AI assistance on reader accuracy and interpretation time, inter-reader agreement, and cross-site reproducibility.

03

Conditions studied

  • Gastric Cancer Stage
  • Gastric Cancer Patients Undergoing Gastrectomy

Browse trials for

Keywords

  • Gastric cancer
  • stage
  • artificial-intelligence
  • detection
  • contrast-enhanced CT
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will enroll adult patients (≥18 years old) with a confirmed diagnosis of gastric cancer (adenocarcinoma) who have undergone contrast-enhanced CT (CECT) as part of their standard preoperative evaluation. Participants will be selected from both internal and external cohorts, with inclusion from multiple centers to assess cross-site reproducibility and generalizability of the AI model.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed gastric cancer;
  2. preoperative contrast-enhanced CT performed;
  3. no evidence of distant on baseline staging;
  4. curative-intent management with complete postoperative histopathology.

Exclusion criteria

Exclusion Criteria:

  1. prior treatment before surgery;
  2. non-diagnostic or poor-quality CT precluding evaluation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
8,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1 (Internal Derivation Cohort)

    Retrospective case-only cohort of adults with pathologically confirmed gastric cancer who underwent preoperative contrast-enhanced CT at the sponsoring institution. Existing CT images and clinical/pathology records will be used to train and test the AI model and to estimate diagnostic performance for T and N staging.

    Diagnostic Test: CT scan

  • Cohort 2 (External Validation Cohort A)

    Independent retrospective case-only cohort from an external hospital with the same inclusion/exclusion criteria. Used solely for external validation to assess reproducibility across sites and scanners.

    Diagnostic Test: CT scan

  • Cohort 3 (External Validation Cohort B)

    A second independent retrospective validation cohort from another institution to further test generalizability.

    Diagnostic Test: CT scan

Interventions

  • Diagnostic testCT scan

    preoperative contrast-enhanced CT

06

What researchers measure

Primary outcomes

  1. Diagnostic performance of the AI model for staging

    The primary outcome is the diagnostic accuracy of the AI system for four-class T staging (T1-T4) and N staging (N0-3) based on contrast-enhanced CT. The AI performance will be assessed using accuracy, area under the receiver operating characteristic curve (AUC), and micro-AUC for internal and external cohorts.

    Time frame: 3 years

Secondary outcomes

  1. Reader Accuracy with AI Support

    This outcome measures the accuracy of radiologists in classifying gastric cancer stagewhen aided by the AI system compared to manual classification without AI assistance. Accuracy will be compared between different radiologist experience levels.

    Time frame: 3 years

  2. Survival time

    Calculate the survival time of gastric cancer patients from the point of diagnosis and treatment initiation.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Dec 2028, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Nov 26, 2025
StartActual
Aug 1, 2025
Primary completionEst.
Dec 30, 2028
CompletionEst.
Dec 30, 2028
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07250347
Collaborators
Jiangsu Cancer Institute & Hospital, Zhengzhou University, Peking University First Hospital
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Aug 1, 2025
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Nov 26, 2025

Study contacts

Zhang Yudong, PHD, MD
Contact
zhangyd3895@njmu.edu.cn
+8618251966069
Qiong Li
Contact
njmu_lq@163.com
+8618351977281
Zhang Yudong
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion